Lupus & antiphospholipid syndrome
Budd Chiari syndrome associated with antiphospholipid syndrome: Clinical characteristics and prognosis of 17 patients from single center
Authors' conclusion
APS patients with BCS may have a higher risk of recurrent thrombosis and mortality.
Study context
- Population
- Patients with thrombotic antiphospholipid syndrome (APS) ± systemic lupus erythematosus (SLE), single centre, 1982–2023thrombotic APS
- Participants
- 194 patients
- Exposure
- APS with Budd-Chiari syndrome (BCS) vs non-BCS vascular thrombotic APS
- BCSn = 17
- Outcome
- Recurrent thrombosis
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
Observational data: associations, not effects.
Further findings
Recurrent thrombosis
- Higher adjusted global APS score (aGAPSS) in BCS vs non-BCS
Second prothrombotic factor among BCS patients
- Second prothrombotic factor detected
- 6
- Heterozygous factor V Leiden mutation
- 3
- Pregnancy period
- 3
- SLE flare
- 2
BCS as first thrombotic event
- BCS was the first thrombotic event
- 8
- Of these, recurrent thrombosis
- 3
Damage (damage index for APS (DIAPS)) and mortality
- DIAPS similar in BCS and non-BCS
- Higher mortality in BCS
Original publication
Budd Chiari syndrome associated with antiphospholipid syndrome: Clinical characteristics and prognosis of 17 patients from single center. Lupus. Published 21 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →